Rhythm Biosciences (ASX:RHY) ROCE %: -309.26% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rhythm Biosciences ROCE %?

Rhythm Biosciences ASX:RHY -1.16% ROCE % is -309.26% as of Dec. 2025. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rhythm Biosciences's annualized ROCE % for the quarter that ended in Dec. 2025 was -309.26%.

Rhythm Biosciences  (ASX:RHY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rhythm Biosciences ROCE % Related Terms

Rhythm Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences ROCE % Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial -369.49 -243.60 -171.82 -199.07 -461.72

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -154.13 -734.65 43.88 -314.21 -309.26

Rhythm Biosciences ROCE % Calculation

Rhythm Biosciences's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-3.763/( ( (1.519 - 0.562) + (2.832 - 2.159) )/ 2 )
=-3.763/( (0.957+0.673)/ 2 )
=-3.763/0.815
=-461.72 %

Rhythm Biosciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-4.376/( ( (2.832 - 2.159) + (3.099 - 0.942) )/ 2 )
=-4.376/( ( 0.673 + 2.157 )/ 2 )
=-4.376/1.415
=-309.26 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -309.26% mean?
Rhythm Biosciences (ASX:RHY) has a ROCE % of -309.26% as of Dec. 2025.
Is Rhythm Biosciences' ROCE % too high?
Rhythm Biosciences' current ROCE % is -309.26%.
How does Rhythm Biosciences' ROCE % compare to TMO and DHR?
Rhythm Biosciences' ROCE % of -309.26% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Rhythm Biosciences's current ROCE % is -309.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (ASX:RHY) has a current ROCE % of -309.26%. The current ROCE % is -309.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Rhythm Biosciences (ASX:RHY), the current ROCE % is -309.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.